Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Genmab ADR (NASDAQ: GMAB) closed at $19.93 up 2.94% from its previous closing price of $19.36. In other words, the price has increased by $2.94 from its previous closing price. On the day, 2.6 million shares were traded.
Ratios:
For a deeper understanding of Genmab ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.52. For the most recent quarter (mrq), Quick Ratio is recorded 5.32 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Leerink Partners Upgraded its Market Perform to Outperform on February 13, 2025, while the target price for the stock was maintained at $27.
Valuation Measures:
As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.30, and their Forward P/E ratio for the next fiscal year is 11.17. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.25. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.79 while its Price-to-Book (P/B) ratio in mrq is 2.39.
Stock Price History:
Over the past 52 weeks, GMAB has reached a high of $30.41, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is -1.61%, while the 200-Day Moving Average is calculated to be -11.41%.
Shares Statistics:
A total of 635.50M shares are outstanding, with a floating share count of 614.73M. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.87% stake in the company.
